Leerink Partnrs Forecasts McKesson’s Q1 Earnings (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Equities research analysts at Leerink Partnrs increased their Q1 2026 earnings per share estimates for shares of McKesson in a report issued on Friday, May 9th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $8.73 per share for the quarter, up from their previous estimate of $8.34. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson’s Q2 2026 earnings at $8.27 EPS, Q3 2026 earnings at $9.39 EPS and FY2028 earnings at $48.22 EPS.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.83 by $0.29. The business had revenue of $90.82 billion for the quarter, compared to analysts’ expectations of $94 billion. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.18 EPS.

A number of other equities analysts have also recently weighed in on the company. Cfra Research cut McKesson from a “moderate buy” rating to a “hold” rating in a report on Friday, April 4th. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company lifted their price target on McKesson from $641.00 to $691.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Morgan Stanley lifted their price target on McKesson from $642.00 to $745.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 2nd. Finally, Bank of America lifted their price target on McKesson from $755.00 to $800.00 and gave the stock a “buy” rating in a research note on Friday. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, McKesson currently has a consensus rating of “Moderate Buy” and an average price target of $686.69.

McKesson Stock Up 0.6%

NYSE:MCK opened at $694.12 on Monday. The business’s 50-day moving average price is $678.24 and its two-hundred day moving average price is $621.72. McKesson has a twelve month low of $464.42 and a twelve month high of $728.48. The stock has a market cap of $86.99 billion, a P/E ratio of 31.78, a PEG ratio of 1.29 and a beta of 0.53.

Institutional Trading of McKesson

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ST Germain D J Co. Inc. boosted its stake in McKesson by 350.0% during the fourth quarter. ST Germain D J Co. Inc. now owns 117 shares of the company’s stock valued at $67,000 after buying an additional 91 shares during the last quarter. Graypoint LLC boosted its stake in McKesson by 3.9% during the fourth quarter. Graypoint LLC now owns 1,006 shares of the company’s stock valued at $573,000 after buying an additional 38 shares during the last quarter. Czech National Bank boosted its stake in McKesson by 4.2% during the fourth quarter. Czech National Bank now owns 27,524 shares of the company’s stock valued at $15,686,000 after buying an additional 1,108 shares during the last quarter. Brookstone Capital Management boosted its stake in McKesson by 42.8% during the fourth quarter. Brookstone Capital Management now owns 10,473 shares of the company’s stock valued at $5,969,000 after buying an additional 3,137 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its stake in McKesson by 29.0% during the fourth quarter. Capital Investment Advisors LLC now owns 2,379 shares of the company’s stock valued at $1,356,000 after buying an additional 535 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 188 shares of the company’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the sale, the executive vice president now owns 1,051 shares in the company, valued at approximately $640,679.09. This represents a 15.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares of the company’s stock, valued at approximately $36,276,465.36. The trade was a 12.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,110 shares of company stock worth $10,855,706 over the last quarter. 0.11% of the stock is currently owned by insiders.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Monday, June 2nd will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, June 2nd. McKesson’s dividend payout ratio is currently 13.00%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.